ViiV Healthcare files patent infringement litigation over bictegravir

8 February 2018

Within hours of gaining US approval for its new HIV treatment Biktarvy, which combines Descovy (emtricitabine/tenofovir alafenamide) with the integrase strand transfer inhibitor bictegravir, US biotech major Gilead Sciences (Nasdaq: GILD) has been slapped with a patent lawsuit.

ViiV Healthcare, the HIV specialist majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), with Pfizer Inc. and Shionogi Limited as shareholders, on Wednesday announced that it has filed patent infringement litigation against Gilead over bictegravir in the USA and Canada.

The US case is filed in the District Court for the District of Delaware and the patent is US patent No 8,129,385. The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No 2,606,282.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK